PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.

Slides:



Advertisements
Similar presentations
Eli Lilly and Company – Tailored Therapeutics and Diagnostics © Eli Lilly and Company 2012 The views and opinions expressed herein and/or during the accompanying.
Advertisements

The Statisticians Role in Pharmaceutical Development
Creating a new class of drugs.. THE BIG QUESTION Why invest in any drug development company? Eventually everyone struggles with their own health or the.
Steven D. Vaughn, DVM Director Office of New Animal Drug Evaluation Center for Veterinary Medicine U. S. Food and Drug Administration June 6, 2012 Embracing.
Pharma/BIOTECH industry overview
Patrick Vallance Head of Drug Discovery GlaxoSmithKline
Michel Goldman, Executive Director Innovative Medicines Initiative (IMI)
1 Confidential Science of Stem Cells and Potential Applications Andrea Hunt February 22, 2008.
The Accelerated Cure Project for MS 1 Suffolk University November 7 th, 2011 Robert N. McBurney, Chief Executive Officer A New Model to Speed the Pace.
SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
ICARE Member Reports ETP seeks to improve incentives and encourage commercial investment in new therapies. (Treatments reach patients only by commercial.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
The NIH Roadmap for Medical Research
1 Global New Employee Orientation Workshop Welcome.
Improving Animal and Human Health by Accelerating Veterinary Centered Entrepreneurship.
EVOLVING PUBLIC HEALTH AND HEALTH CARE LANDSCAPE AND OPPORTUNITIES FOR CANCER COMMUNICATION NCI Health Communication and Informatics Research Branch CPCRN.
ONE HEALTH DR. Theo Kanellos Director, Strategic Alliances Zoetis International Services.
Innovation for a Better Run World Melvina Tarazi, Vice President, Business Development and Industries, SAP MENA Woman Mean Business.
Global Leadership in Medical Innovation: “Ours to Lose”
Bernard A Fox, PhD Immediate Past President and Chair, Executive Council Society for Immunotherapy of Cancer (SITC) Defining the Critical Hurdles in Cancer.
The Business Research Company Healthcare. Typical Healthcare Projects Copyright TBRC Business Research. All Rights Reserved. 2 Market Analysis Product.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Einari Kanerva founder and CEO Its My Life – Also in Corporate Wellness.
Managing Medical R&D Defining and Realizing Clinical and Commercial Value David J. Wierz Senior Director Commercial Investment & Pricing Strategy Wyeth-Ayerst.
1 Michael V. Novinski President and Chief Executive Officer November 6, 2008 Third Quarter 2008 Earnings Conference Call.
How can we work together? Partnering with Industry: An Investigator’s Perspective Robert L. Coleman, MD M. D. Anderson Cancer Center.
Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.
2008 AHCA/NCAL National Quality Award Program - Step III Overview - Jon Frantsvog Ira Schoenberger Tim Case.
The Importance of a Strategic Plan to Eliminate Health Disparities 2008 eHealth Conference June 9, 2008 Yvonne T. Maddox, PhD Deputy Director Eunice Kennedy.
The Global Context. WHO and IAPB VISION 2020 launched in 1999 A world in which no one is needlessly blind and where those with unavoidable vision loss.
Establishing a Global Vaccine Development Fund Peter Hale The Foundation for Vaccine Research Washington, DC Consultation on Financing of R&D Preparedness.
Vaccine Enterprise & Collaboration Bill Snow, Director 19 January 2013 CHVI Afri-Can Forum.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
1 Enterprise Innovation Institute Growth: Industries Community Policy & Research Services Bringing innovation to local and state government entities Technology-based.
The Role of New Markets Advisors in Healthcare Case Study in Pharma.
The Role of New Markets Advisors in Healthcare Case Study in Health Insurance Innovation.
The Role of New Markets Advisors in Healthcare Case Study in Medical Devices.
Roadmap Economic Impact & Funding Opportunities Dr Stephen Hillier
CONFIDENTIAL 0 0 Paul Stoffels, M.D. Chief Scientific Officer Worldwide Chairman, Pharmaceuticals.
Patient Engagement throughout the Biopharmaceutical Lifecycle: Tips for Effective Patient Advocate/Industry Collaboration to Improve Patient Access and.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
1 Communicating with Venture Capitalists to Fund Your Research Raising Venture Capita l Michael Jirousek, Ph.D. Senior Advisor, Innovation Support Center.
Endoscopy Visualization Systems - Medical Devices Pipeline Assessment
Positron Emission Tomography (PET) Systems - Medical Devices Pipeline Assessment, 2016
Developing and Broadening Specialists in Research & Development
Research & development
MEP Interest Group on Brain, Mind and Pain
Providing Hope to Patients and their Families Around the World!
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Industry Perspective: Expanded Access Programs
The FDA Early Feasibility Study Pilot and the Innovation Pathway
Our Company Ashman group is a new generation for Ashman Global in field of pharmaceutics and Nutraceuticals Our divisions embrace research and science.
Gestora brasileiro focada exclusivamente na área da saúde.
Monoclonal Antibodies Market Forecast, Market Size - Ken Research.
Finland, a Global Testbed for Personalized Cancer Research?
Introduction to TransCelerate
What Makes a Novel Technology Innovative?
Welsh Health Innovation Technology Accelerator
Introduction to TransCelerate
Clinical and Translational Science Awards Program
Elanco Animal Health Partnering for Growth Bruce E. Taillon, PhD.
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Clinical Trials Challenges
The only prescription with unlimited refills. Regular exercise (150 minutes per week) lowers risk of developing heart disease, high blood pressure,
GLOBAL HEALTHCARE CONTRACT RESEARCH OUTSOURCING MARKET 2017 – 2025 Published by :Accurize Market Research Pvt. Ltd. Copyright © 2019 Accurize Market Research.
Expert Speak: How Pharma Companies Can Grow Their Business?
Global Specialty Pharmaceuticals Market. Report Description and Highlights According to Renub Research report "Specialty Pharmaceuticals Market, by Country.
Presentation transcript:

PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model

CONFERENCE OF MONTREAL Information of December 31 st 2013 OUR GROUP SANOFI AT A GLANCE We are a global healthcare company engaged in the research, development, manufacturing and marketing of healthcare solutions. present in more than 100 countries more than employees A comprehensive offer of pharmaceuticals, vaccines and innovative therapeutic solutions 112 Industrial sites in 41 countries R&D A major biopharmacy player 45% of revenues generated by biologics 80% of development projects are biologics €33 bn * In sales in 2013 * €32,951 M

Multiple Sclerosis Diabetes Oncology Rare Diseases Cardio-Metabolic Diseases Immunology Vaccines Animal Health CONFERENCE OF MONTREAL We act as one to discover and develop therapies that prevent, treat and cure disease. 9 projects and vaccines in clinical development* high potential projects in late stage development* 49 SANOFI R&D ACCELERATE INNOVATION FOR PATIENTS Our main areas of research include: *Information provided as of February 6 th, 2014

CONFERENCE OF MONTREAL OUR RESPONSIBILITY CHANGE THE R&D INNOVATION MODEL The classic INNOVATION model Belief that advances in basic sciences can be easily translated to human disease A linear process from discovery to development to market with little interactions throughout the innovation cycle Focus on novel (but not necessarily validated) targets in humans A strategy of “Many Shots on Goal” A non-linear process that takes into account provider, purchaser and user metrics including pipeline activity, clinical success, regulatory approval, patient access, satisfaction of unmet need and overall value to society A greater understanding of human disease Open innovation and partnership The new INNOVATION model Raising the batting average!

CONFERENCE OF MONTREAL OUR PRESIDENT OF R&D PATIENTS ARE THE MISSING LINK

CONFERENCE OF MONTREAL Increasing public awareness & improving clinical trial education MAKING CLINICAL TRIALS PATIENT FRIENDLY SO WHAT ARE WE DOING ABOUT IT? What do patients know about clinical research? How do they get their facts? How do they know if a study exists? Do they ever hear the results? Bringing patients within the project team e.g. Diabetes Patient Advisors input into study designs, innovation & outreach strategies Innovating to ease patient experience e-informed consent e-technology (e.g. telemetry) Point of care technologies (e.g. Dried Blood Spots)

CONFERENCE OF MONTREAL SO WHAT ARE WE DOING ABOUT IT? BEFORE AND BEYOND CLINICAL TRIALS Opportunities exists from target to use Target identification Path to proof of concept Effective value Access Partner in Patient Health (PiPH) initiative EU-NA PiPH Council Collaborate | Innovate Challenge Newly created position of Chief Patient Officer

CONFERENCE OF MONTREAL OUR “RAISON D’ETRE” ACCELERATE INNOVATION FOR PATIENTS